Neoadjuvant Chemotherapy for the Local Advanced Breast Cancer

Abstract

후 국소진행성 유방암에서 유도화학요법의 효용성이 여 IIIB, and 16 (13.1%) in IIIC at diagnosis. 10 patients (8.2%) have shown CR, 85 (69.7%) patients PR, and the remaining 27 (22.1%) patients showed NR. The overall response rate to neoadjuvant chemotherapy was 77.5%. However, only 51 (41.8%) were demonstrated to have pathologically downstaged results. There were 32 loco-regional recurrences and 59 distant metastases. All of the initial clinical stage, clinical response to neoadjuvant chemotherapy, and pathologic stage influenced the final outcome of 10 year OS, LRRFS, DRFS. However, in multivariate analysis pathologic stage after neoadjuvant chemotherapy was the most influencing factor on the final outcome. Conclusion: Pathologic stage after neoadjuvant chemotherapy could be the most important prognostic factor of the LABC. (Journal of Korean Breast Cancer Society 2002; 5:311-318)